Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review
Conclusions
Lisdexamfetamine dimesylate may have clinical utility for BED in adolescents, but randomized, placebo-controlled studies of its efficacy, tolerability, and safety in this population are needed. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect
Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and extended release, allowing providers to customize a patient's regimen for maximum tolerability and compliance. Although bupropion HCl's safety and tolerability have been demonstrated through several clinical trials, there are still a number of adverse effects that have been reported in the literature. These inclu...
Source: Clinical Neuropharmacology - November 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Rocuronium Continuous Infusion for Profound Neuromuscular Blockade: A Systematic Review and Meta-analysis
Conclusions
Rocuronium continuous infusion for profound neuromuscular blockade presents inherent advantages in terms of maintenance and stability of the paralysis. Further studies should address the methodological approaches and benefits/drawbacks of this approach.
Registration number: CRD42018106626 (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2019 Category: Neurology Tags: Review Article Source Type: research
Efficacy and Placebo Response of Multimodal Treatments for Primary Insomnia: A Network Meta-Analysis
Conclusions
The pharmacotherapy seems the most effective in improving sleep efficiency. However, the optimal therapeutic regimen is still uncertain. In addition, the placebo response is significant and robust in treatments of primary insomnia. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Conclusions
Our findings demonstrated that adjunctive treatment with propentofylline is effective in alleviating disease severity and improving irritability in ASD patients. However, larger studies with longer durations are required to confirm these results. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - November 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
The Naranjo Scale and Tardive Syndromes, a Historical Perspective
No abstract available (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Letter to the Editor Source Type: research
Treatment of Catatonia in Frontotemporal Dementia: A Lesson From Zolpidem Test
Conclusions
In dementia patients, different catatonic symptoms may show differential responses to the therapeutic agents and, if verbal symptoms are dominant, it is worthy to try zolpidem in the early stage. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Priapism With Methylphenidate Use in a Preschool-Aged Boy Resolved With Switching to Atomoxetine
Conclusions
This case report suggests that ATX may be safely used in some children who experienced priapism with MPH. Future studies are needed to clarify the risk factors and etiologic mechanisms of this adverse reaction. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism
Conclusions
Bupropion has previously generally been discontinued 1 week prior DAT imaging, which meets the recommended, albeit arbitrary, time interval of 5 plasma clearance half-lives before the scan. One-week discontinuation of bupropion before DAT imaging may be insufficiently short. Our case shows that longer medication washout and rescan may be needed when there is contradiction between the imaging result and clinical outcome in patients with medications affecting DAT binding. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Hypothermia Associated With Melatonin Ingestion in a Child With Autism
We present a case of hypothermia in an autistic child with a sleep disorder whose body temperature decreased to 34°C after a single dose of melatonin. Hypothermia continued for 2 more days, but her nighttime sleeping problems decreased. This case is important because it demonstrates the possible risk of hypothermia with melatonin use in children with autism with a sleep disorder. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Case Reports Source Type: research
Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy
Conclusions
Apomorphine infusion is a minimally invasive therapy and therefore very easy to discontinue if difficulties arise. This fact might explain the high dropout rate of this technique. Successful long-term adherence to APO therapy requires a multidisciplinary health care team approach including regular patient follow-up and assessment and prompt resolution of queries and concerns. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study
Conclusions
In this retrospective study, improvement in neurological symptoms during PGB therapy was observed in the total population, despite the presence of a distal, sensory axonal neuropathy, as evidenced by neurophysiological examination. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina
Conclusions
The effectiveness of fingolimod in a newly real-world setting was consistent with information provided from phase III clinical trials. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Cerebrospinal Fluid Concentrations of Nimodipine Correlate With Long-term Outcome in Aneurysmal Subarachnoid Hemorrhage: Pilot Study
Conclusions
Cerebrospinal fluid nimodipine concentrations measured during hospital drug infusion showed a correlation with long-term clinical outcome in patients with aneurysmal subarachnoid hemorrhage. These very preliminary data suggest that CSF concentrations monitoring may have some value in managing these patients. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations
Objectives
IPX203 is an investigational oral extended-release capsule formulation of carbidopa and levodopa. The pharmacodynamics and efficacy of IPX203 were compared with immediate-release carbidopa-levodopa (IR CD-LD) in this open-label, rater-blinded, multicenter, crossover study in patients with advanced Parkinson disease (PD).
Methods
Twenty-eight patients were randomized to 2 weeks of treatment with IR CD-LD followed by IPX203 or IPX203 followed by IR CD-LD. Pharmacokinetic and motor assessments were conducted on days 1 and 15 of each treatment period. Efficacy was assessed using a 3-day PD diary. Pharmacodynami...
Source: Clinical Neuropharmacology - September 1, 2019 Category: Neurology Tags: Original Articles Source Type: research
